The United Kingdom’s Department for International Development (DFID) has selected PATH as a partner in pioneering work to prevent, diagnose, and treat malaria and diarrhea in low-resource settings. PATH will lead an innovative product development partnership to more quickly reach children and adults with new lifesaving technologies for both diseases.
Diarrhea and malaria are two of the leading causes of illness and death in low-resource settings, killing nearly 1.5 million people—mostly children—each year. People in poor areas are disproportionately affected by these diseases, and more solutions are needed that will meet their specific needs.
The new partnership builds on a promising portfolio of vaccines, drugs, diagnostics, and other projects that PATH already leads to tackle both diseases. The partnership will enable a more coordinated effort to accelerate the development of new and existing approaches and take these technologies to scale. PATH will address key gaps and bottlenecks that affect the supply of important health tools, the availability of affordable vaccines, and the development of new drugs and diagnostics.
PATH’s effort is one of nine product development partnerships that will be funded over the next five years through a £138 million total investment from DFID. Together, these include the following:
These partnerships will enable the public and private sectors to share expertise, costs, and risks while advancing lifesaving solutions.
PATH has nearly 40 years of developing and managing product development partnerships to advance global health solutions. Under the new DFID projects, we will tap into our expertise across the full product development value chain—from investigating new ideas to scaling up products—to bring more high-quality solutions to the communities that need them.
Specifically our work will address:
Our partnership will leverage the strengths of numerous partners, such as governments, academic institutions, commercial manufacturers, research groups, and nonprofit organizations, to tackle complex social and technological challenges that slow development.
Our model examines products in the early stages of development and identifies those that are most likely to succeed, thereby lowering risk for pharmaceutical companies, vaccine manufacturers, and other commercial developers. PATH often partners with developers to carry these products forward through late-stage development.
This approach encourages companies to bring new products to market that can be affordable, sustainable, and lifesaving for millions of children.